期刊文献+

白血病患者化疗后应用白介素-2治疗的临床观察 被引量:5

Clinical observation of the effect of interleukin-2 on leukemia patients after chemotherapy
下载PDF
导出
摘要 目的:探讨白血病患者化疗后应用白介素-2(IL-2)治疗的临床疗效。方法:将50例白血病患者随机分治疗组和对照组,治疗组化疗后加入IL-2 100万U/d×14d,对照组单用化疗,监测两组治疗前、后T淋巴细胞亚群及化疗后患者的临床疗效、不良反应。结果:治疗组治疗2周后T淋巴细胞亚群水平明显高于治疗前及对照组化疗后(P<0.05)。治疗组完全缓解(CR)率与总有效(OR)率与对照组相近,但粒细胞缺乏发生率、持续时间及感染发生率低于对照组(P<0.05)。结论:应用IL-2对化疗后患者进行治疗可明显提高T淋巴细胞亚群水平,并可减少化疗后不良反应。 Objective: To investigate the clinical effect of interleukin-2 (IL-2) on leukemia patients after chemotherapy. Methods: 50 leukemia patients were randomized into the treatment group and the control group. The treatment group received 1,000,000 units of IL-2 daily for 14 days immedi ately after chemotherapy, while the control group received no IL-2 after chemotherapy. The level changes of T lymphocyte subgroup, the clinical effect and the adverse reactions of the patients before and after the treatment with IL-2 were monitored. Results: After 14 days' treatment, the level of T lymphocyte subgroup in the treatment group was significantly higher than those before the treatment and those in the control group after chemotherapy (P〈0.05). The complete remission (CR) rate and overall response (OR) rate in the treatment group was similar to those in the control group, but the incidence rate of agranulocytosis, duration and the incidence rate of infection in the treatment group was significantly lower than those in the control group (P〈0.05). Conclusion: The application of IL-2 to treating leukemia patients after chemotherapy can obviously increase the level of T lymphocyte subgroup and release the adverse effects caused by chemotherapy.
出处 《华夏医学》 CAS 2014年第2期15-17,共3页 Acta Medicinae Sinica
关键词 白血病 化学治疗 白介素-2 T淋巴细胞亚群 leukemia chemotherapy interleukin-2 T lymphocyte subgroup
  • 相关文献

参考文献7

  • 1]张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:106-116,131-134.
  • 2刘小莲,朱万寿,邓志萍,颜沛云,黄世俭,黄锡梅,李胜华.白血病患者化疗后应用白介素Ⅱ对T淋巴细胞亚群的影响[J].中国实用医药,2009,4(2):27-28. 被引量:4
  • 3Chen X X, Wang J, Woltring D, et al. Histone dynamics on the interleukin-2 Gene in response to T-Cell activation [J]. Molecular and Cellula Biology, 2005, 25 (8) : 3209- 3219.
  • 4Brune M, Castaigne S, Catalano J, et al. Improved leuke- mia free survival after post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial [J]. Blood, 2006,108 : 88-96.
  • 5刘昊,郭智.自体造血干细胞移植治疗恶性淋巴瘤后大剂量白细胞介素2过继免疫对长期生存的影响[J].中国组织工程研究与临床康复,2011,15(6):1132-1136. 被引量:6
  • 6Blaise D, Stoppa A M, Veins P, et al. Intensive immuno- therapy with recombinant IL-2 after autologous bone marrow transplantation is associated with a high incidence of bacterial infections[J]. Bone Marrow Transplantation, 1992,10:193.
  • 7Van der Vliet H J, Koon H B, Yue S C, et al. Effects of the administration of high-dose interleukin-2 on immuno- regulatory cell subsets in patients with advanced melano- ma and renal cell cancer[J]. Clin Cancer Res, 2007, 13 (1) .. 2101-2108.

二级参考文献10

共引文献9

同被引文献43

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部